Osimertinib / TumCCA Cancer Research Results

Osi, Osimertinib: Click to Expand ⟱
Features:
Osimertinib works by selectively inhibiting the activity of EGFR, which is a protein that plays a critical role in the growth and survival of cancer cells. By blocking the activity of EGFR, osimertinib prevents the growth and proliferation of cancer cells, leading to tumor shrinkage and improved survival.
Osimertinib has been shown to be effective in patients with NSCLC who have specific EGFR mutations. In the AURA3 trial, osimertinib significantly improved progression-free survival (PFS) compared with platinum-based chemotherapy. In the FLAURA trial, osimertinib significantly improved PFS and overall survival (OS) compared with erlotinib or gefitinib.
TumCCA, Tumor cell cycle arrest: Click to Expand ⟱
Source:
Type:
Tumor cell cycle arrest refers to the process by which cancer cells stop progressing through the cell cycle, which is the series of phases that a cell goes through to divide and replicate. This arrest can occur at various checkpoints in the cell cycle, including the G1, S, G2, and M phases. S, G1, G2, and M are the four phases of mitosis.
Scientific Papers found: Click to Expand⟱
1002- SSE,  Osi,  Adag,    Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
- in-vitro, Lung, H1975 - in-vitro, Lung, H385
Apoptosis↑, Ferroptosis↑, DNMT1↓, TET1↑, TumCCA↑, cl‑PARP↑, cl‑Casp3↑, Cyt‑c↑, BIM↑, NOXA↑, Apoptosis↑, ROS↑, ER Stress↑, UPR↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 2,   BIM↑, 1,   cl‑Casp3↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   NOXA↑, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,   UPR↑, 1,  

DNA Damage & Repair ⓘ

DNMT1↓, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Migration ⓘ

TET1↑, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TumCCA, Tumor cell cycle arrest
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:253  Target#:322  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page